The SARS antibodies are not cross-reactive with SARS-Cov-2. However, we can potentially use artificial intelligence to design variants of the existing SARS antibodies which are cross-reactive with SARS-CoV-2.
Brett Averso, CTO, and I recently had a follow up discussion on our first coronavirus chat. Brett provided visualizations and commentary on coronavirus (SARS-CoV-2), ACE2, SARS-CoV-2 with SARS overlay, and antibody fragments to help people better understand the threat we’re currently facing, as well as put it in its proper context. Brett also discussed the role AI can play in finding an effective treatment for COVID-19.
Columbia Data Science Institute recently covered EVQLV’s work towards developing therapeutic candidates against COVID-19 with Immunoprecise Antibodies.
The 4 stages are fairly simple: luck, avoiding failure, learning from failure, learning from success. The biggest takeaway is the importance of the 4th stage. It’s far too common for us to achieve a desired outcome and never evaluate how we could have improved our performance.
Brett Averso, CTO, and I linked up to discuss the coronavirus (SARS-CoV-2). Brett covered what exactly the coronavirus is, the threat it currently presents, how we can best protect ourselves and our loved ones against infection, and what EVQLV is doing to address the outbreak.
Legitimate concerns notwithstanding, Andrew Satz and I recently discussed how EVQLV understands and utilizes AI. During the discussion, Andrew proposed the idea that far from stripping us of our humanity, AI may allow us to become more human.
AI or artificial intelligence is a term that gets thrown around constantly in the tech space. In our most recent discussion, Andrew Satz (CEO, EVQLV), covers what it means when a company says they’re leveraging AI, how EVQLV is utilizing AI, the different types of AI (hint: that “A” doesn’t always mean artificial), and perhaps most interestedly, how AI can make us more human.
Talem Therapeutics, a subsidiary of ImmunoPrecise, and EVQLV announced a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus (coronavirus).